Form D · Biotechnology
TC BioPharm (Holdings) plc
Holytown, Motherwell, X0 · CIK 0001872812
Offering snapshot reported Dec 13, 2022 · SEC filing
- Reported sold
- $7.35M Offering amount: $7.35M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 30, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 13, 2022 | Initial | $7,350,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $551K
- Finders' fees
- $0
- Form D file number
- 021-467306
The placement agent is also entitled to a management fee of $73,500, non-accountable expenses of $85,000 and warrants to purchase 110,250 ADSs.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Dec 13, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Bonyhadi | Director |
| James Culverwell | Director |
| Bryan Kobel | Director |
| Michael Leek | Director |
| Arlene Morris | Director |
| Edward Niemczyk | Director |
| Martin Thorp | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Maxim 1, 2 Parklands Way
Holytown, Motherwell, X0, ML14WR
Holytown, Motherwell, X0, ML14WR